Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602576 · ClinicalTrials.gov registry record · Phase 2
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
NCT00602576 is a Phase 2 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 169 participants.
The verdict
NCT00602576, a Phase 2 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving temozolomide together with sorafenib may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different schedules of temozolomide when given together with sorafenib to compare how well they work in treating patients with metastatic or unresectable melanoma.
Interventions
- DRUG temozolomide
- DRUG sorafenib tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2005-01-01 |
| Est. Completion | 2009-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00602576
The ClinicalTrials.gov registry entry for NCT00602576 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00602576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00602576 about?
NCT00602576 is a clinical study titled "Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma". RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking bl...
What is the current status of trial NCT00602576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2005-01-01. Estimated completion is 2009-07-26.
What interventions are being tested in trial NCT00602576?
The interventions under investigation include: temozolomide (DRUG), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00602576?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.